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ABSTRACT
Many infectious diseases disproportionately affect people in the developing world.
Cryptococcal meningitis is one of the most common mycoses in HIV-AIDS
patients, with the highest burden of disease in sub-Saharan Africa. Current best
treatment regimens still result in unacceptably high mortality rates, and more
effective antifungal agents are needed urgently. Drug development is hampered by
the difficulty of developing effective antifungal agents that are not also toxic to
human cells, and by a reluctance among pharmaceutical companies to invest in
drugs that cannot guarantee a high financial return. Drug repurposing, where
existing drugs are screened for alternative activities, is becoming an attractive
approach in antimicrobial discovery programs, and various compound libraries are
now commercially available. As these drugs have already undergone extensive
optimisation and passed regulatory hurdles this can fast-track their progress to
market for new uses. This study screened the Screen-Well Enzo library of 640
compounds for candidates that phenotypically inhibited the growth of Cryptococcus
deuterogattii. The anthelminthic agent flubendazole, and L-type calcium channel
blockers nifedipine, nisoldipine and felodipine, appeared particularly promising and
were tested in additional strains and species. Flubendazole was very active against all
pathogenic Cryptococcus species, with minimum inhibitory concentrations of
0.039–0.156 mg/mL, and was equally effective against isolates that were resistant to
fluconazole. While nifedipine, nisoldipine and felodipine all inhibited Cryptococcus,
nisoldipine was also effective against Candida, Saccharomyces and Aspergillus. This
study validates repurposing as a rapid approach for finding new agents to treat
neglected infectious diseases.
Subjects Microbiology, Mycology, Drugs and Devices, Infectious Diseases
Keywords Cryptococcus, Cryptococcosis, Drug repurposing, Antifungal drugs, Flubendazole,
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INTRODUCTION
Cryptococcal meningitis is a devastating fungal disease that disproportionately affects
the poorest, most resource-limited, underdeveloped regions of the world, where the
health burden is extremely high. Those who are most at risk are patients who are
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immunocompromised, including HIV/AIDS populations and patients receiving rigorous
immunosuppressive treatments such as chemotherapy. Mortality rates are unacceptably
high and vary significantly with demography, with estimates as low as 9% among
patients in developed countries compared to 70% in sub-Saharan Africa (Park et al.,
2009), where cryptococcal meningitis clinically presents in up to 40% of HIV/AIDS
patients (Dzoyem et al., 2012; Rajasingham et al., 2017). This high mortality is largely
attributable to lack of access and difficulty in administering the most effective standard
treatment, amphotericin B combined with flucytosine (Kneale et al., 2016; Perfect et al.,
2010), which is expensive and requires medical infrastructure for therapeutic monitoring
due to adverse effects including nephrotoxicity, hepatotoxicity and bone marrow
suppression (Kneale et al., 2016; Loyse et al., 2013; Meiring et al., 2016). Fluconazole is
commonly used in place of amphotericin B and flucytosine; however, as it is a fungistatic
drug, it does not effectively clear fungal burden and is associated with clinical relapse,
greater mortality and poorer clinical outcomes, as well as the risk of inducing drug
resistance (Bicanic et al., 2006; Jarvis et al., 2014; Smith et al., 2015). Overall, there is
an urgent need for new antifungal treatments that are more effective, economical,
accessible and available to regions where they are needed most. Drug repurposing, or
repositioning, is becoming an increasingly popular avenue in drug discovery. This is
the establishment of a new indication for a drug entity that has been previously
approved for another purpose by authoritative bodies such as the US Food and
Drug Administration (FDA). For pharmaceutical industries and drug developers,
repurposing offers attractive benefits as previously established pharmacokinetic and
pharmacodynamics profiles provide the potential to fast-track drugs through the
development pipeline, avoiding substantial costs associated with expensive clinical trials
(Oprea & Mestres, 2012). The antidepressant sertraline is a leading example of a non-
antifungal drug in the process of being repurposed for cryptococcal meningitis. First
discovered through a drug screen in 2010, sertraline has potent fungicidal activity against
Cryptococcus and is synergistic in combination with fluconazole (Zhai et al., 2010, 2012).
In vivo, sertraline alone or in combination with fluconazole reduced fungal burden in
infected mice (Zhai et al., 2012). Most importantly, sertraline achieved more efficient
clearance of fungal burden in HIV-infected patients in Uganda, with no relapse during
the clinical study (Rhein et al., 2016).
Cryptococcus encompasses a range of phylogenetically discrete genotypes and species
that can cause cryptococcal meningitis. Cryptococcus neoformans is an opportunistic
pathogen commonly infecting groups with compromised immune systems. C. neoformans
is the most well-studied cryptococcal species and has been the main target of drug
discovery efforts to identify new anti-cryptococcal agents. However, C. deuterogattii
(formerly known as C. gattii genotype VGII) has recently emerged as a primary pathogen,
responsible for recent outbreaks affecting otherwise immunocompetent individuals
(Byrnes et al., 2010; Hagen et al., 2015). In this study, we phenotypically screened the
Enzo library consisting of 640 FDA-approved agents against C. deuterogattii to identify
compounds with novel anti-cryptococcal activity. We report multiple compounds that
inhibited the growth of C. deuterogattii and that were subsequently screened against
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various pathogenic fungal species to determine the spectrum of activity. Flubendazole
was the most potent compound and was found to specifically target Cryptococcus
species. Nifedipine, nisoldipine and felodipine demonstrated antifungal activity
towards Cryptococcus species and to varying degrees towards other yeast and mould
pathogens. Our findings highlight the value of repurposing strategies to rapidly screen
drug libraries that can reveal new classes of antifungal agents for further development.
METHODS
Strains
Fungal strains used in this study are listed in Tables 1 and 2. Strains were maintained
as glycerol stocks stored at -80 C. Strains were grown on sabouraud dextrose agar (SDA)
for 48 h at 30 C before use.
Enzo drug library and drug stocks
The Screen-Well FDA-approved drug library was purchased from Enzo Life Sciences
(catalogue no. BML-2841; Farmingdale, NY, USA). The 640 compounds in this library
were provided at 2 mg/mL in dimethyl sulfoxide (DMSO). Flubendazole (FLB),
mebendazole (MEB), benomyl (BEN), nisoldipine (NIS), nifedipine (NIF), felodipine
(FEL), niguldipine (NIG), amphotericin B (AMB), itraconazole (ITZ), voriconazole
(VRZ) and 5-flucytosine (5FC) were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Fluconazole (FLC) was obtained from Cayman Chemical (Ann Arbor, MI, USA). Stock
solutions of amphotericin B, itraconazole and voriconazole were prepared at 1.6 mg/mL
in water; 5-flucytosine was made at 6.4 mg/mL in water; fluconazole was made at
12.8 mg/mL in water and all remaining drugs were dissolved in DMSO at 2 mg/mL.
All compounds were stored at -80 C.
Table 1 Minimum inhibitory concentrations of flubendazole and a series of calcium channel
blockers against Cryptococcus, Saccharomyces, Candida and Aspergillus species.
Genus Species Strain MIC (mg/mL)a
FLB NIF NIG FELO NISO
Cryptococcus deuterogattii R265 0.078 10 >40 10–20 5–20
gattii WM179 0.078 5 >40 10 10–40
tetragattii M391 0.078 10 >40 20 40
neoformans H99 0.078 10 >40 10 20–40
Saccharomyces cerevisiae S288c >40 40 >40 >40 10
Candida parapsilosis ATCC22019 >40 >40 >40 >40 20
albicans M23 >40 >40 >40 >40 40
glabrata M27 >40 20 >40 >40 10
glabrata M63 >40 20 >40 >40 10
Aspergillus fumigatus ATCC204305 >40 >40 >40 >40 10–20
Notes:
MIC ranges are given for compounds with variable results. MICs greater than 40 mg/mL (shaded in grey) indicate where
an MIC was not obtained at the highest testing concentration.
FLB, flubendazole; NIF, nifedipine; NIG, niguldipine; FELO, felodipine; NISO, nisoldipine.
a MICs obtained from four biological replicates each with technical duplicates.
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Primary drug screening
We evaluated all 640 FDA-approved compounds in the Enzo library for efficacy
against C. deuterogattii strain R265. In the primary screen, each compound was tested
once at 10 mg/mL and once at 40 mg/mL using 96-well flat-bottom microtitre plates.
Amphotericin B was included as a standard antifungal control. Untreated cells and
Table 2 Minimum inhibitory and minimum fungicidal concentrations of flubendazole against Cryptococcus species from varied sources.
Species (molecular genotype) Strain Source Geographic origina MIC (mg/mL) MFC (mg/mL)
FLCb FLBc FLBc
C. gattii (VGI) ENV316 Environmental Australia 0.078 0.156
PNG14 Clinical Papua New Guinea 0.078 0.078
2005/215 Clinical France 0.078 0.078
V15/571_103 Veterinary Australia 0.078 0.078
C. deuterogattii (VGII) 97/170 Clinical France 64 0.078 0.078
R265 Clinical Canada 4 0.078 0.078
CBS1930 Veterinary Aruba 0.078 0.078
ICB184 Environmental Brazil 0.039 0.039
14.1431 Veterinary Australia 32 0.039 0.078
LA499 Clinical Columbia 32 0.039 0.039
V5 Veterinary Australia 8 0.039 0.078
03-201073 Clinical Australia 16 0.078 0.078
C. bacillisporus (VGIII) VBP62270 Veterinary Australia 0.078 0.078
97/427 Clinical Mexico 0.156 0.313
WM161 Environmental USA 0.156 0.156
B13C Clinical Asia 0.078 0.156
C. tetragattii (VGIV) MMRL3013 Clinical Africa 0.039–0.156 0.039–0.156
M250 Clinical Malawi 0.156 0.156
WM779 Veterinary South Africa 0.078 0.078
MMRL2650 Clinical India 0.039 0.078
C. neoformans (VNI) 1043.ENR.STOR Clinical Africa 0.078 0.156
1020.CLIN1 Clinical Africa 0.039 0.078
H99 Clinical USA 4 0.039 0.039
WM625 Clinical Australia 8 0.02 0.039
WM385 Clinical Thailand 4 0.039 0.039
C. neoformans (VNII) 1023.ENR Clinical Africa 0.039 0.078
1045.ENR.STOR Clinical Africa 0.078 0.156
C. neoformans (VNBI) 1050.ENR.CLIN Clinical Africa 0.078 0.156
C. neoformans (VNBII) 1033.ENR Clinical Africa 0.039 0.078
1052.ENR.STOR Clinical Africa 0.039 0.078
1049.THER1.STOR Clinical Africa 0.039 0.039
Notes:
a USA, United States of America; FLU, fluconazole.
b FLC (fluconazole) MIC data obtained from Chong et al. (2010) and Lai et al. (2016).
c FLB (flubendazole) MICs and MFCs are shown as modes from four biological replicates, each with technical duplicates. A concentration range is given where variable
results were obtained.
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broth-only controls were also included. Cell suspensions of C. deuterogattii strain R265
were prepared following the reference methods of the Clinical and Laboratory Standards
Institute (CLSI) for broth dilution antifungal susceptibility testing of yeasts (Clinical and
Laboratory Standards Institute (CLSI), 2008b). Briefly, an isolated colony of C. deuterogattii
strain R265 from a 2-day old plate was inoculated into 1 mL of Yeast Nitrogen Broth
(YNB, pH 7; Sigma-Aldrich, St. Louis, MO, USA). A working cell suspension was
prepared at 1  106 to 5  106 cells/mL by cell counting using a haemocytometer, and
was diluted 1:100. Final cell concentrations were 0.5  103 to 2.5  103 cells/mL with a
final volume of 200 mL per well. Plates were incubated at 37 C (humidified) without
agitation for 72 h. Initial ‘hit’ candidates were defined as compounds that visibly inhibited
the growth of C. deuterogattii.
To identify compounds with the greatest potential for repurposing as novel antifungal
agents, compounds that complied with the following were excluded from further
assessment: (i) compounds that were active only at concentrations greater than 10 mg/mL;
(ii) compounds that were known antineoplastic agents or had otherwise unwanted adverse
profiles; and (iii) currently established antifungal agents or non-antifungal agents with
antifungal activity that had already been described and assessed at the time of testing.
Broth microdilution test
The in vitro antifungal activities of ‘hit’ compounds were re-evaluated using the stocks
supplied in the library as well as from independently sourced stocks, and testing was
extended to additional pathogenic fungal species (Tables 1 and 2). Drug compounds were
serially diluted twofold in YNB medium (final concentrations: 0.078125–40 mg/mL).
Amphotericin B was included as an antifungal control for reference. Niguldipine, a
member of the same class of 1,4-dihydropyridines (calcium channel blocker (CCB))
that had been identified as a non-‘hit’ compound in the screen was included as a negative
control for the CCB series. Fungal cell suspensions were prepared following the CLSI
standard method for broth dilution antifungal susceptibility testing of yeasts (Clinical
and Laboratory Standards Institute (CLSI), 2008b) or filamentous fungi (Clinical and
Laboratory Standards Institute (CLSI), 2008a). Plates were incubated without agitation at
35 or 37 C (humidified) for 48 h for non-Cryptococcus species or 72 h for Cryptococcus
species. The minimum inhibitory concentration (MIC) was determined as the lowest
drug concentration at which a compound visibly inhibited growth (100% for FLB, MEB,
BEN, NIF, NISO, FELO, NIG, AMB and 5FC; 80% for FLC, ITZ and VRZ). To obtain
the minimum fungicidal concentration (MFC), 30 mL from each dilution well at the
MIC concentration and higher was spread onto SDA plates. The MFC was defined as the
lowest drug concentration that yielded three or fewer colonies after 72 h incubation
(Espinel-Ingroff et al., 2002). All microdilution assays were tested in technical duplicates
with at least two biological replicates unless otherwise specified.
Checkerboard microdilution assay
Checkerboard assays determine the interaction between two drugs based on the fractional
inhibitory concentration index (FICI) value. Interactions can be synergistic (FICI  0.5),
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additive/indifferent (0.5 < FICI  4) or antagonistic (FICI > 4) (Lai et al., 2016).
Briefly, drug A (flubendazole, mebendazole or benomyl) was serially diluted from 0.31
to 0.0024 mg/mL and aliquoted in a 96-well flat-bottom plate and combined with
drug B that was serially diluted and aliquoted in the following concentration ranges:
amphotericin B (2–0.016 mg/mL); fluconazole (32–0.25 mg/mL); itraconazole
(2–0.016 mg/mL); voriconazole (2–0.016 mg/mL); 5-flucytosine (32–0.25 mg/mL).
FICI values were calculated as:
FICI ¼ MIC drug A in combination
MIC drug A alone
þMIC drug B in combination
MIC drug B alone
All drug combinations were tested against C. deuterogattii strain R265 and C. neoformans
strain H99 as per CLSI guidelines. All plates were incubated at 37 C and inhibition
was read visually at 72 h.
Time-kill assay
Cryptococcus neoformans strain H99 was grown overnight to exponential phase in YNB
media, shaking (180 rpm) at 37 C. Cells were adjusted to 1  106 cells/mL using a
haemocytometer and sub-cultured in fresh YNB media. Three hours post sub-culturing,
two 50 mL aliquots were taken. One culture was not treated, while the other was treated
with 0.06 mg/mL flubendazole (1.5  MIC). Cultures were returned to the shaking
incubator and monitored for cell growth at 2, 3, 4, 5, 6, 9 and 24 h post-treatment.
At each time point, each culture was sampled in technical duplicates, serially diluted in
milli-Q water and spread onto SDA plates. All plates were incubated at 37 C and observed
at 48 h and 72 h for viability counts.
RESULTS
Primary drug screening identifies non-antifungal compounds with
anti-cryptococcal activity
The preliminary screening of the Enzo library revealed a diverse variety of compounds
that inhibited the growth of C. deuterogattii strain R265 (Fig. 1; Fig. S1; Table S1).
A significant proportion (15%) of ‘hits’ from this initial screen were antineoplastic drugs.
This antifungal affect may be attributed to the cytotoxic nature of these compounds
since cryptococcal and humans cells are eukaryotic and may share cellular structures
and processes that result in non-selective toxicity. For this reason, this group of drugs
were not pursued as potential antifungal candidates. Using the selection criteria described
in the “Methods” section, 16 of the remaining compounds identified in the primary
screen were short-listed for further evaluation by MIC assays against C. deuterogattii.
Antifungal activity was confirmed for ten compounds using drug stocks sourced from
the library. The most potent compounds (MICs < 5 mg/mL) were aripiprazole,
nisoldipine, oxatomide, flubendazole, nifedipine and anethole-trithione. Lack of
commercial availability restricted further evaluation to flubendazole, an anthelmintic
drug (Fig. 2), and nisoldipine and nifedipine, which are antihypertensive CCBs (Fig. 3).
Truong et al. (2018), PeerJ, DOI 10.7717/peerj.4761 6/18
Felodipine and niguldipine, which are CCBs structurally related to nifedipine and
nisoldipine, were also included in the assay.
In vitro spectrum of antifungal activity of CCBs and flubendazole
To investigate the spectrum of antifungal activity, MICs were determined for nisoldipine,
nifedipine, felodipine, niguldipine and flubendazole against nine additional strains
from four fungal species (Table 1). MIC assays using independently sourced drug
stocks confirmed the MICs established for C. deuterogattii strain R265 and demonstrated
a diverse range of antifungal activities against other fungal strains and species (Table 1).
Flubendazole was the most potent compound against Cryptococcus species with MICs
as low as 0.078 mg/mL, but was ineffective even at the highest tested concentration
(40 mg/mL) against other fungal species. The series of CCBs presented an interesting
array of activities across the fungal species. Nifedipine demonstrated consistent antifungal
activity against the Cryptococcus species (5–10 mg/mL) and inhibited Candida glabrata,
Total = 54
Antineoplastic
Antihypertensive
Antipsychotic
Anthelmintic
Antihistamine
Antiparkinsonian
Other
20%
15%
13%
9%
7%
6%
6%
24%
Antifungal
Figure 1 Pie chart of drug compound classes that inhibited the growth of C. deuterogattii strain
R265 at 10 mg/mL. A total of 54 compounds inhibited the growth of C. deuterogattii strain R265 at
10 mg/mL. Classes of drugs included: antifungal (20%); antineoplastic (15%); antihypertensive (13%);
antipsychotic (9%); anthelmintic (7%); antihistamine (6%); antiparkinsonian (6%); other (24%).
Full-size DOI: 10.7717/peerj.4761/fig-1
Figure 2 Chemical structure of flubendazole. Flubendazole was drawn with BIOVIA Draw 2017 R2
(Version 17.2; Dassault Syste`mes, San Diego, CA, USA). Full-size DOI: 10.7717/peerj.4761/fig-2
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an emerging fungal pathogen, with anMIC of 20mg/mL. In contrast, nisoldipine had higher
and more variable MICs against different Cryptococcus species (5–40 mg/mL) and was
the only drug that had activity against all nine fungal species. Niguldipine was not effective
at the highest tested concentration against the fungal strains in this assay, while felodipine
demonstrated activity against the Cryptococcus species with MICs between those of
nifedipine and nisoldipine, but was only active against Cryptococcus species.
Antifungal activities of flubendazole
To test whether flubendazole is broadly active across Cryptococcus species, we extended
the study to encompass all members of the C. gattii species complex, as well as the
major molecular genotypes of C. neoformans (Table 2; Table S2), including veterinary,
clinical and environmental isolates from various geographic locations. Flubendazole
inhibited all isolates of both Cryptococcus species at consistently low concentrations
(MIC 0.039–0.156 mg/mL). Furthermore, for isolates where fluconazole MIC data were
available, flubendazole was found to be equally effective regardless of fluconazole
susceptibility (Table 2; Table S2).
To explore the inhibitory effect of flubendazole on Cryptococcus cells, cell viability
was assessed using a time-kill assay and determining the MFC in a microwell format.
Analysis by time-kill curve over 24 h demonstrated that Cryptococcus cells exposed to
flubendazole had slowly declining growth for up to 9 h post-treatment prior to loss of
viability (Fig. 4; Table S3). Microbroth dilution assays generated MFC values that were
similar to the respective MIC values (MFC 0.039–0.156 mg/mL; Table 2).
Nisoldipine
Nifedipine
Niguldipine
Lacidipine
Felodipine
Figure 3 Chemical structures of 1,4-dihydropyridine calcium channel blockers: nisoldipine,
nifedipine, felodipine, niguldipine and lacidipine. The core structure shared by members of the
1,4-dihydropyridine class is shaded in blue. Large side groups are shaded in pink. Chemical structures
were drawn with BIOVIA Draw 2017 R2 (Version 17.2; Dassault Syste`mes, San Diego, CA, USA).
Full-size DOI: 10.7717/peerj.4761/fig-3
Truong et al. (2018), PeerJ, DOI 10.7717/peerj.4761 8/18
To explore interactions with current, commonly used antifungals, flubendazole and
the other benzimidazole agents mebendazole and benomyl was tested in combination
with amphotericin B, fluconazole, itraconazole, voriconazole and 5-flucytosine against
C. deuterogattii and C. neoformans in a checkerboard assay. All combinations produced
additive/indifferent results and no synergistic or antagonistic interactions were seen
(Table 3; Tables S4–S5).
DISCUSSION
Despite the major health problems caused by cryptococcal infections, there is a lack of
new antifungal drugs. Promising, albeit limited, research has demonstrated the potential
for repurposing drugs and the implications of this approach for treating cryptococcal
infections have been highlighted (Butts et al., 2013; Dehdashti et al., 2013; Joffe et al., 2017;
Rabjohns et al., 2013; Rhein et al., 2016; Samantaray et al., 2016; Spitzer et al., 2011). Most
Figure 4 Time-kill assay of C. neoformans strain H99 treated with flubendazole. C. neoformans cells
in logarithmic growth phase were treated with 0.06 mg/mL flubendazole and incubated at 37 C with
shaking. The growth of treated cells tracked the untreated control cells for 3–4 h post-treatment and
began to slow thereafter. Viability declined markedly by 9 h and did not recover by 24 h. Growth curve
was generated using Prism 7 (Version 7.0b; GraphPad Software, La Jolla, CA, USA).
Full-size DOI: 10.7717/peerj.4761/fig-4
Table 3 Fractional inhibitory concentration index values of flubendazole, mebendazole and benomyl in combination with various antifungals
against C. neoformans H99 and C. deuterogattii R265.
Cryptococcus species Benzimidazole Fractional inhibitory concentration indexa
AMB FLC ITZ VRZ 5FC
C. neoformans H99 Flubendazole (0.75–2) (1.5–2) (1.5–3) (1–1.25) 2
Mebendazole (1–2) 1.5 (1–2.5) (1–1.125) (1.5–2)
Benomyl (0.75–1.5) (1.25–1.5) (1.25–1.5) (0.75–1.125) (1.25–1.5)
C. deuterogattii R265 Flubendazole (1.5–3) (2–3) (1.5–2.5) (1–1.5) (1–1.5)
Mebendazole (1.5–2.5) (1.5–2.5) (1–2.5) (0.75–1.5) 1.5
Benomyl (1–2.25) (1.25–1.5) (1.25–1.5) (0.625–1) (1–1.25)
Note:
a AMB, amphotericin B; FLC, fluconazole; ITZ, itraconazole; VRZ, voriconazole; 5FC, 5-flucytosine. Data shown were produced from two independent replicates.
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studies have screened the Prestwick Chemical Library (n = 1,120), the Library of
Pharmaceutically Active Compounds (n = 1,280) and the National Institutes of Health
clinical collection (n = 727). Within the last decade, these drug screening studies have
led to the discovery of multiple non-antifungal compounds with antifungal activities,
which were often novel and fungicidal (Butts et al., 2013; Dehdashti et al., 2013; Joffe et al.,
2017; Rabjohns et al., 2013; Samantaray et al., 2016; Spitzer et al., 2011). Some have
demonstrated the ability to target intracellular C. neoformans in macrophages and
cryptococcal biofilms and to act synergistically with the widely-used drug fluconazole
(Butts et al., 2013;Dehdashti et al., 2013; Joffe et al., 2017; Rabjohns et al., 2013; Samantaray
et al., 2016; Spitzer et al., 2011). However, these studies have focused on C. neoformans
with only one reporting on C. deuterogattii strain R265 (Spitzer et al., 2011). There can
be significant differences in target specificity among closely related genera and species
of pathogenic yeasts (Chong et al., 2010; Spitzer et al., 2011). Thus, while C. neoformans
and C. deuterogattii are sibling species, drugs may work differently between them.
Here we report the first screening of a 640-compound FDA-approved library against
C. deuterogattii strain R265, with subsequent testing of additional pathogenic cryptococci
(encompassing an extensive list of C. neoformans species and the entire C. gattii species
complex) and other fungi.
Repurposing CCBs as antifungal agents
Calcium channel blockers, widely used in the treatment of hypertension, are broadly
divided into dihydropyridines and non-dihydropyridines classes (Catterall, 2011). Our
screen identified nifedipine, felodipine and nisoldipine (Table 1; Fig. 3) as having
antifungal activity against Cryptococcus. These are all 1,4-dihydropyridines and
therefore present as intriguing leads for a potential new class of antifungal drugs.
Members of the 1,4-dihydropyridine CCB group share a core phenyl group
attached to a 1,4-dihydropyridine that has two ester side groups (Fig. 3). Variations in
side groups may account for the diverse antifungal activities observed, as compounds
with the bulkier side groups (lacidipine and niguldipine) were ineffective against
C. deuterogattii. Nifedipine, felodipine, nisoldipine and niguldipine target L-type calcium
channels—one of five types of voltage-gated calcium channels (VGCCs) designated
L-, N-, P/Q-, R- and T-type (Catterall, 2011). In the model yeast Saccharomyces cerevisiae,
Cch1 and Mid1 are homologs of the mammalian VGCCs, and L-type CCBs are known
to inhibit fungal growth via a Cch1–Mid1 protein channel complex located in the
plasma membrane (Prole & Taylor, 2012; Teng et al., 2008). Cch1 acts as the calcium
channel and has homologs in almost all fungi, while Mid1 is a regulatory subunit that
interacts with Cch1 to mediate calcium influx (Hong et al., 2013). Hence, it appears likely
that the antifungal effects of CCBs involve the Cch1–Mid1 calcium channel.
Our findings support a growing body of evidence suggesting a crucial role of
calcium regulation and calcium channels in determining the growth and survival of yeasts
under stressful conditions (Hong et al., 2010; Liu et al., 2006; Peiter et al., 2005). In
C. neoformans, Cch1 facilitates calcium entry with Mid1 when there is a depletion of
intracellular calcium (Hong et al., 2010). In the presence of the calcium chelator BAPTA,
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the growth ofcch1mutants is markedly diminished at elevated temperature (25–38.5 C),
a key virulence factor that is critical for human infection (Liu et al., 2006). Cch1 and Mid1
also appear linked to the regulation of intracellular redox under cell stress, as S. cerevisiae
cch1 andmid1 (single- and double-knockout) mutants are sensitive to cold stress (10 C)
and iron toxicity due to a compromised ability to cope with oxidative stress (Peiter et al.,
2005). Cell growth can be re-established following supplementation with either 10 mM
calcium or reduced glutathione (an antioxidant), indicating that a functional Cch1–Mid1
complex is essential for stress tolerance (Peiter et al., 2005).
As well as possessing antifungal properties, CCBs have also been shown to act
synergistically with fluconazole against fluconazole-resistant and -susceptible strains of
C. albicans (Liu et al., 2016). Interestingly, CCBs alone or in combination with fluconazole
do not significantly alter the gene expression level of CCH1 and MID1 (Liu et al.,
2016) suggesting that either the cell is not sensing a disruption to calcium homeostasis,
or CCBs act on targets other than calcium channels. Recently, a screen of the Prestwick
Chemical Library of FDA-approved small molecules identified fendiline hydrochloride,
a non-dihydropyridine CCB, as having unique activity to potentiate phagosomal
killing of intracellular C. neoformans in host macrophages (Samantaray et al., 2016).
Although it has a very different structure to the antifungal CCBs identified here,
fendiline is an L-type CCB, suggesting this class of CCBs may be the most promising
for antifungal drug development. Furthermore, the antifungal activity of L-type CCBs
in combination with standard antifungals have been characterised in C. albicans and
Aspergillus (Afeltra et al., 2004; Liu et al., 2016). As hypertensive agents, L-type CCBs are
currently administered in long term use with relatively minimal side effects (Chrysant,
2003). Of clinical relevance, some CCBs including nifedipine and nisoldipine can traverse
the blood–brain barrier and may therefore be able to treat cryptococcal meningitis (Gaggi,
Cont & Gianni, 1993). We therefore suggest L-type CCBs are promising leads for
repurposing and redevelopment as potential new antifungal agents.
Repurposing flubendazole as an anti-cryptococcal agent
Flubendazole is an anthelmintic drug belonging to a family of benzimidazole carbamates.
First introduced in 1980, it is currently used to treat parasitic gastrointestinal worm
infections in humans and animals (Fig. 2) (Spagnuolo et al., 2010). Flubendazole acts
by binding to and inhibiting the polymerisation of tubulin, a cytoskeletal protein that
polymerises to form microtubules (Chatterji et al., 2011; Cruz & Edlind, 1997; Spagnuolo
et al., 2010). Microtubules play major roles in various cell processes including division,
motility, adhesion and intracellular transport (Chatterji et al., 2011). Benzimidazoles
have been found to act selectively against fungal tubulin and not mammalian tubulin,
possibly due to differences in their b-tubulin sequence (Cruz & Edlind, 1997).
Benzimidazoles were originally developed as agricultural fungicides prior to their use
as anthelmintic drugs (Horton, 2000). While the antifungal activities of benzimidazoles
and their potential to be developed as anti-cryptococcal agents have been known for
over two decades (Patent US5434163) (Cruz, Bartlett & Edlind, 1994; Del Poeta et al.,
1998; Edlind & Cruz, 1995), no further development as antifungal agents has occurred
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since 1998 (Del Poeta et al., 1998). Our study indicated that flubendazole is fungicidal
at extremely low concentrations against C. neoformans and C. deuterogattii (Table 2).
Our findings show that flubendazole equally inhibits pathogenic and environmental
isolates of Cryptococcus, as well as strains that are resistant to fluconazole. This indicates
that flubendazole may be an effective treatment against genetically and physiologically
diverse Cryptococcus species and strains. As resistance to fluconazole is frequently induced
during prolonged treatment and has been associated with clinical failure in
Cryptococcus-infected patients (Bicanic et al., 2006; Jarvis et al., 2014; Smith et al., 2015),
flubendazole may have promise as a second-line therapy when fluconazole fails,
particularly in resource-poor regions where there are often no suitable alternatives.
Flubendazole interferes with normal cell growth as early as 3 h post-treatment and
continues to render treated Cryptococcus cells unviable (Fig. 4), and in a microwell
format with 72 h incubation the MFC values were either the same or one increment
higher than the respective MIC values (Table 2). This indicates that flubendazole is a
fungicidal drug, and with the correct clinical administration, it could effectively clear
fungal burden. As high fungal burden is a strong determinant for mortality and overall
poor clinical outcomes, and currently amphotericin B is the only fungicidal agent that
is effective against cryptococcosis, this reinforces the potential utility of flubendazole
as an anti-cryptococcal agent (Jarvis et al., 2014). It is noted however, that unlike
amphotericin B, flubendazole does not act synergistically with other standard antifungal
agents, consistent with previously published data (Table 3) (Joffe et al., 2017).
The current findings support a recent screening of 727 compounds in the National
Institute of Health Clinical Collection (Joffe et al., 2017). Flubendazole and three
related anti-helminthic benzimidazoles (mebendazole, albendazole and triclabendazole;
sharing the benzimidazole scaffold) were among 17 compounds active against
C. neoformans (Joffe et al., 2017). However, that study focused on mebendazole on the
basis that the drug is able to penetrate the blood–brain barrier. Low MIC and MFC values
were reported, and efficacy against biofilms and against cryptococcal cells internalised
in macrophages were shown, along with additive activity when combined with
amphotericin B (Joffe et al., 2017). Flubendazole may mirror the antifungal capabilities
observed for mebendazole as they share structural similarities, and there is evidence
that like mebendazole, flubendazole can traverse the blood–brain barrier (Te´llez-Giro´n
et al., 1984) making these compounds favourable candidates for the treatment of
cryptococcal meningitis. However, as flubendazole is formulated to treat gastrointestinal
worms, it is not yet known whether it would be able to reach therapeutic concentrations
in the brain required to elicit an antifungal effect.
The precise mechanism underlying the antifungal activity of flubendazole is unclear,
however it is thought that it targets b-tubulin in C. neoformans (Cruz & Edlind, 1997).
The kill-curve demonstrated initial growth after treatment followed by declining viability
and death at 9 h, which is consistent with a mode of action that works by interfering
with cell growth and division. In Echinococcus granulosus, a tapeworm parasite,
flubendazole has been found to disrupt a wide spectrum of cellular homeostatic
mechanisms, including energy metabolism and calcium homeostasis. In the latter it
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appears to increase cytosolic calcium from extracellular and intracellular stores (Cumino,
Elissondo & Denegri, 2009), demonstrating an interesting overlap with the CCBs
outlined above.
Overall, flubendazole (and more generally the benzimidazole scaffold) may be a
promising starting point for the treatment of cryptococcal disease. This view is further
encouraged by a lack of evidence of serious adverse side effects in patients undergoing
anti-helminthic treatment and in mice experimentally treated with flubendazole (Ceballos
et al., 2009; Feldmeier et al., 1982; Lasse`gue et al., 1984; Te´llez-Giro´n et al., 1984). In
preliminary cryptococcal meningitis studies, flubendazole demonstrated fungicidal
activity in a hollow fibre infection model and efficacy in vivo, reducing fungal burden
in both a rabbit and mice model (Nixon et al., 2018). However, whether flubendazole
can accumulate in the brain to concentrations that are clinically achievable and able to
elicit an antifungal effect, and whether this can be sustained in the absence of adverse
reactions, remains unknown and requires more extensive in vivo testing.
CONCLUSION AND PERSPECTIVES
This study, and others like it, demonstrate the utility of drug repurposing to discover
novel agents for the treatment of neglected diseases like cryptococcosis. L-type CCBs
and anti-helminthic benzimidazoles have emerged in different drug screens and appear
particularly promising as both are registered for use in other applications, are well
tolerated and appear able to traverse the blood–brain barrier. Phenotypic screening
approaches have repeatedly demonstrated utility, ensuring that identified drug
candidates possess the desired phenotype of inhibiting growth of the pathogen prior to
further mechanistic investigations. In addition to serendipitously finding molecules
or compounds that can be used directly in the clinic, repurposing strategies may
identify related classes of compounds with activity and thus provide a scaffold for
subsequent medicinal chemistry to initiate lead drug discovery programs.
Currently, it costs billions of dollars for a drug to successfully obtain FDA-approval and
reach market. To help alleviate this financial risk and provide an incentive, there are moves
by regulatory agencies in the United States and Europe to encourage academic and
pharmaceutical research to bring new antimicrobials to market. For example, the
GAIN Act (Generating Antibiotic Incentives Now) grants companies manufacturing a
‘qualified infectious disease product’ an additional period of market exclusivity, with
or without a patent, to ensure a better return on their investment. This applies to the
repurposing of existing drugs with new indications, and should encourage pharmaceutical
companies to develop some of these newly identified agents as therapeutics for fungal
diseases, which are urgently required in global health.
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